Stock Track | Bio-Techne Plunges 5.89% Pre-market on Q1 Earnings and Revenue Miss

Stock Track

Nov 05, 2025

Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first quarter fiscal 2026 financial results. The company's earnings and revenue figures fell short of analysts' expectations, triggering a sell-off among investors.

The biotechnology firm reported adjusted earnings per share (EPS) of $0.42, slightly below the $0.43 consensus estimate provided by IBES. More significantly, Bio-Techne's revenue for the quarter came in at $286.555 million, missing the projected $293.9 million mark by a considerable margin. This revenue shortfall appears to be the primary catalyst for the stock's sharp decline.

Despite the disappointing top and bottom-line results, Bio-Techne did report some positive figures. The company's Q1 net income stood at $38.185 million, with an operating income of $47.658 million and a pretax profit of $47.991 million. However, these metrics were not enough to offset investor concerns about the missed earnings and revenue targets. As the market digests this information, all eyes will be on Bio-Techne's ability to realign with analyst expectations in the coming quarters.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1175331413"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1175331413\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1175331413?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175331413","market":"nz","top_or_hot":-1,"title":"Stock Track | Bio-Techne Plunges 5.89% Pre-market on Q1 Earnings and Revenue Miss","media":"Stock Track","content":"<p>Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first quarter fiscal 2026 financial results. The company's earnings and revenue figures fell short of analysts' expectations, triggering a sell-off among investors.</p>\n\n<p>The biotechnology firm reported adjusted earnings per share (EPS) of $0.42, slightly below the $0.43 consensus estimate provided by IBES. More significantly, Bio-Techne's revenue for the quarter came in at $286.555 million, missing the projected $293.9 million mark by a considerable margin. This revenue shortfall appears to be the primary catalyst for the stock's sharp decline.</p>\n\n<p>Despite the disappointing top and bottom-line results, Bio-Techne did report some positive figures. The company's Q1 net income stood at $38.185 million, with an operating income of $47.658 million and a pretax profit of $47.991 million. However, these metrics were not enough to offset investor concerns about the missed earnings and revenue targets. As the market digests this information, all eyes will be on Bio-Techne's ability to realign with analyst expectations in the coming quarters.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bio-Techne Plunges 5.89% Pre-market on Q1 Earnings and Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bio-Techne Plunges 5.89% Pre-market on Q1 Earnings and Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-05 19:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first quarter fiscal 2026 financial results. The company's earnings and revenue figures fell short of analysts' expectations, triggering a sell-off among investors.</p>\n\n<p>The biotechnology firm reported adjusted earnings per share (EPS) of $0.42, slightly below the $0.43 consensus estimate provided by IBES. More significantly, Bio-Techne's revenue for the quarter came in at $286.555 million, missing the projected $293.9 million mark by a considerable margin. This revenue shortfall appears to be the primary catalyst for the stock's sharp decline.</p>\n\n<p>Despite the disappointing top and bottom-line results, Bio-Techne did report some positive figures. The company's Q1 net income stood at $38.185 million, with an operating income of $47.658 million and a pretax profit of $47.991 million. However, these metrics were not enough to offset investor concerns about the missed earnings and revenue targets. As the market digests this information, all eyes will be on Bio-Techne's ability to realign with analyst expectations in the coming quarters.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"","article_id":"1175331413","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175331413","pubTimestamp":1762342350,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first quarter fiscal 2026 financial results. The company's earnings and revenue figures fell...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation"},"translate_title":"个股追踪|Bio-Techne盘前暴跌5.89%因Q1盈利和营收未达预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1},"content_text":"Bio-Techne (TECH) shares tumbled 5.89% in pre-market trading on Wednesday following the release of its first quarter fiscal 2026 financial results. The company's earnings and revenue figures fell short of analysts' expectations, triggering a sell-off among investors.\nThe biotechnology firm reported adjusted earnings per share (EPS) of $0.42, slightly below the $0.43 consensus estimate provided by IBES. More significantly, Bio-Techne's revenue for the quarter came in at $286.555 million, missing the projected $293.9 million mark by a considerable margin. This revenue shortfall appears to be the primary catalyst for the stock's sharp decline.\nDespite the disappointing top and bottom-line results, Bio-Techne did report some positive figures. The company's Q1 net income stood at $38.185 million, with an operating income of $47.658 million and a pretax profit of $47.991 million. However, these metrics were not enough to offset investor concerns about the missed earnings and revenue targets. As the market digests this information, all eyes will be on Bio-Techne's ability to realign with analyst expectations in the coming quarters.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}